PHAT
Phathom Pharmaceuticals, Inc.$10.45+0.18 (+1.75%)Prev Close$10.27·MCap$786.4M·P/E—·Vol398.7K·Yield—
▲
Buys (12M)
0
$0.00
▼
Sells (12M)
11
$2.06M
◆
Net Activity
Net Seller
$2.06M
●
Active Insiders
3
last 12 mo
Over the past 12 months, insider activity at Phathom Pharmaceuticals, Inc. (PHAT) has been exclusively selling, with 0 insider purchases totaling $0.00 and 11 insider sales totaling $2.06M. The most recent insider transaction was by Basta Steven L (President and CEO), who sold $80.5K worth of shares on Feb 10, 2026. Phathom Pharmaceuticals, Inc. operates in the Healthcare sector, within the Biotechnology industry, with a market cap of $786.4M.
PHAT Insider Trading Activity
| Date | Insider | Role | Type | Shares | Avg Price | Value | Shares After |
|---|---|---|---|---|---|---|---|
| Feb 10, 2026 | Basta Steven L | President and CEO | Sell | 6,277 | $12.82 | $80.5K | 0 |
| Feb 10, 2026 | Cook Anne Marie | Chief Legal Off. & Corp. Sec. | Sell | 1,535 | $12.82 | $19.7K | 0 |
| Jan 21, 2026 | Breedlove Robert Charles | Principal Accounting Officer | Sell | 776 | $13.61 | $10.6K | 0 |
| Dec 18, 2025 | Breedlove Robert Charles | Principal Accounting Officer | Sell | 230 | $16.28 | $3.7K | 0 |
| Dec 17, 2025 | Basta Steven L | President and CEO | Sell | 31,502 | $15.36 | $483.9K | 0 |
| Dec 17, 2025 | Cook Anne Marie | Chief Legal Off. & Corp. Sec. | Sell | 7,703 | $15.36 | $118.3K | 0 |
| Nov 28, 2025 | Basta Steven L | President and CEO | Sell | 48,375 | $15.62 | $755.6K | 0 |
| Nov 3, 2025 | Breedlove Robert Charles | Principal Accounting Officer | Sell | 524 | $13.51 | $7.1K | 0 |
| Sep 25, 2025 | Basta Steven L | President and CEO | Sell | 48,375 | $11.66 | $564.1K | 0 |
| Sep 5, 2025 | Breedlove Robert Charles | Principal Accounting Officer | Sell | 461 | $12.09 | $5.6K | 0 |
| Jul 16, 2025 | Breedlove Robert Charles | Principal Accounting Officer | Sell | 1,692 | $8.36 | $14.2K | 0 |
| May 21, 2025 | Topper James N | Director | Buy | 3,780 | $3.86 | $14.6K | 0 |
| May 13, 2025 | Topper James N | Director | Buy | 7,420 | $3.30 | $24.5K | 0 |
| May 9, 2025 | Topper James N | Director | Buy | 48,203 | $3.17 | $152.9K | 0 |
| May 6, 2025 | Parikh Asit | Director | Buy | 10,000 | $2.50 | $25.0K | 0 |
| Apr 7, 2025 | Henderson Molly | CFO and CBO | Sell | 3,678 | $4.55 | $16.7K | 0 |
| Mar 13, 2025 | Parikh Asit | Director | Buy | 10,000 | $4.42 | $44.2K | 0 |
| Jul 17, 2024 | Curran Terrie | President and Chief Executive | Sell | 33,848 | $11.72 | $396.7K | 377,734 |
| Jul 17, 2024 | Henderson Molly | CFO and CBO | Sell | 4,325 | $11.72 | $50.7K | 99,447 |
| Jul 17, 2024 | Nabulsi Azmi | Chief Operating Officer | Sell | 10,901 | $11.72 | $127.8K | 240,421 |
| Mar 26, 2024 | Curran Terrie | President and Chief Executive | Sell | 16,851 | $9.11 | $153.5K | 410,784 |
| Jan 25, 2024 | TAKEDA PHARMACEUTICAL CO LTD | 10% Owner | Sell | 3,703,703 | $8.10 | $30.00M4.7% OS | 3,755,583-50% |
| Jan 22, 2024 | Henderson Molly | CFO and CBO | Sell | 6,307 | $7.75 | $48.9K | 98,698 |
| Nov 21, 2023 | Henderson Molly | CFO and CBO | Sell | 2,127 | $7.24 | $15.4K | 103,061 |
| Nov 8, 2023 | Parikh Asit | Director | Buy | 7,500 | $7.81 | $58.6K | 55,000 |
| Nov 3, 2023 | Henderson Molly | CFO and CBO | Sell | 12,492 | $8.88 | $110.9K | 116,869 |
| Jun 5, 2023 | Henderson Molly | CFO and CBO | Sell | 1,960 | $11.41 | $22.4K | 68,506 |
| May 23, 2023 | Henderson Molly | CFO and CBO | Sell | 2,110 | $12.87 | $27.2K | 70,466 |
| Apr 11, 2023 | Nabulsi Azmi | Chief Operating Officer | Buy | 10,000 | $8.26 | $82.6K | 99,567 |
| Apr 11, 2023 | Parikh Asit | Director | Buy | 1,000 | $7.55 | $7.5K | 23,500 |
| Apr 7, 2023 | Curran Terrie | President and Chief Executive | Buy | 12,919 | $7.82 | $101.0K | 188,290 |
| Apr 7, 2023 | Henderson Molly | CFO and CBO | Sell | 3,439 | $7.27 | $25.0K | 72,576 |
| Mar 3, 2023 | Curran Terrie | President and Chief Executive | Sell | 1,436 | $8.54 | $12.3K | 175,371 |
| Mar 3, 2023 | Henderson Molly | CFO and CBO | Sell | 2,032 | $8.53 | $17.3K | 76,015 |
| Feb 14, 2023 | Parikh Asit | Director | Buy | 5,000 | $7.73 | $38.7K | 22,500+29% |
| Jan 20, 2023 | Curran Terrie | President and Chief Executive | Sell | 5,821 | $8.20 | $47.7K | 176,807 |
| Jan 12, 2023 | Parikh Asit | Director | Buy | 5,000 | $7.00 | $35.0K | 17,500+40% |
| Nov 23, 2022 | Curran Terrie | President and Chief Executive | Sell | 1,526 | $9.60 | $14.6K | 83,720 |
| Nov 23, 2022 | Henderson Molly | CFO and CBO | Sell | 2,159 | $9.60 | $20.7K | 43,341 |
| May 16, 2022 | Parikh Asit | Director | Buy | 12,500 | $8.00 | $100.0K | 12,500 |
| May 16, 2022 | Curran Terrie | President and Chief Executive | Buy | 20,500 | $7.41 | $151.8K | 64,595+46% |
| May 16, 2022 | Nabulsi Azmi | Chief Operating Officer | Buy | 20,000 | $8.16 | $163.3K | 785,700 |
| Mar 16, 2022 | TAKEDA PHARMACEUTICAL CO LTD | 10% Owner | Sell | 18 | $19.00 | $342.00 | 7,459,286 |
| Nov 8, 2021 | TAKEDA PHARMACEUTICAL CO LTD | 10% Owner | Sell | 1,000,001 | $20.85 | $20.85M1.3% OS | 1,100,000-48% |
| Oct 8, 2021 | Socks David A | Director | Sell | 18,000 | $32.58 | $586.4K | 1,213,875 |
| Sep 23, 2021 | Socks David A | Director | Sell | 18,000 | $32.63 | $587.4K | 1,233,770 |
| Aug 18, 2021 | Socks David A | Director | Sell | 18,000 | $31.25 | $562.5K | 1,261,137 |
| Jul 9, 2021 | TAKEDA PHARMACEUTICAL CO LTD | 10% Owner | Sell | 2,609 | $35.05 | $91.4K | 871,305 |
| Jul 6, 2021 | TAKEDA PHARMACEUTICAL CO LTD | 10% Owner | Sell | 8,326 | $35.16 | $292.7K | 874,014 |
| Jun 29, 2021 | Socks David A | Director | Sell | 40,000 | $34.05 | $1.36M | 1,275,061 |
Showing 1–50 of 75
1 / 2
PHAT Insider Buying Activity
The following table shows recent insider purchases of Phathom Pharmaceuticals, Inc. (PHAT) stock reported via SEC Form 4 filings.
| Date | Insider | Role | Type | Shares | Avg Price | Value | Shares After |
|---|---|---|---|---|---|---|---|
| May 21, 2025 | Topper James N | Director | Buy | 3,780 | $3.86 | $14.6K | 0 |
| May 13, 2025 | Topper James N | Director | Buy | 7,420 | $3.30 | $24.5K | 0 |
| May 9, 2025 | Topper James N | Director | Buy | 48,203 | $3.17 | $152.9K | 0 |
| May 6, 2025 | Parikh Asit | Director | Buy | 10,000 | $2.50 | $25.0K | 0 |
| Mar 13, 2025 | Parikh Asit | Director | Buy | 10,000 | $4.42 | $44.2K | 0 |
| Nov 8, 2023 | Parikh Asit | Director | Buy | 7,500 | $7.81 | $58.6K | 55,000 |
| Apr 11, 2023 | Nabulsi Azmi | Chief Operating Officer | Buy | 10,000 | $8.26 | $82.6K | 99,567 |
| Apr 11, 2023 | Parikh Asit | Director | Buy | 1,000 | $7.55 | $7.5K | 23,500 |
| Apr 7, 2023 | Curran Terrie | President and Chief Executive | Buy | 12,919 | $7.82 | $101.0K | 188,290 |
| Feb 14, 2023 | Parikh Asit | Director | Buy | 5,000 | $7.73 | $38.7K | 22,500+29% |
| Jan 12, 2023 | Parikh Asit | Director | Buy | 5,000 | $7.00 | $35.0K | 17,500+40% |
| May 16, 2022 | Parikh Asit | Director | Buy | 12,500 | $8.00 | $100.0K | 12,500 |
| May 16, 2022 | Curran Terrie | President and Chief Executive | Buy | 20,500 | $7.41 | $151.8K | 64,595+46% |
| May 16, 2022 | Nabulsi Azmi | Chief Operating Officer | Buy | 20,000 | $8.16 | $163.3K | 785,700 |
PHAT Insider Selling Activity
The following table shows recent insider sales of Phathom Pharmaceuticals, Inc. (PHAT) stock reported via SEC Form 4 filings.
| Date | Insider | Role | Type | Shares | Avg Price | Value | Shares After |
|---|---|---|---|---|---|---|---|
| Feb 10, 2026 | Basta Steven L | President and CEO | Sell | 6,277 | $12.82 | $80.5K | 0 |
| Feb 10, 2026 | Cook Anne Marie | Chief Legal Off. & Corp. Sec. | Sell | 1,535 | $12.82 | $19.7K | 0 |
| Jan 21, 2026 | Breedlove Robert Charles | Principal Accounting Officer | Sell | 776 | $13.61 | $10.6K | 0 |
| Dec 18, 2025 | Breedlove Robert Charles | Principal Accounting Officer | Sell | 230 | $16.28 | $3.7K | 0 |
| Dec 17, 2025 | Basta Steven L | President and CEO | Sell | 31,502 | $15.36 | $483.9K | 0 |
| Dec 17, 2025 | Cook Anne Marie | Chief Legal Off. & Corp. Sec. | Sell | 7,703 | $15.36 | $118.3K | 0 |
| Nov 28, 2025 | Basta Steven L | President and CEO | Sell | 48,375 | $15.62 | $755.6K | 0 |
| Nov 3, 2025 | Breedlove Robert Charles | Principal Accounting Officer | Sell | 524 | $13.51 | $7.1K | 0 |
| Sep 25, 2025 | Basta Steven L | President and CEO | Sell | 48,375 | $11.66 | $564.1K | 0 |
| Sep 5, 2025 | Breedlove Robert Charles | Principal Accounting Officer | Sell | 461 | $12.09 | $5.6K | 0 |
| Jul 16, 2025 | Breedlove Robert Charles | Principal Accounting Officer | Sell | 1,692 | $8.36 | $14.2K | 0 |
| Apr 7, 2025 | Henderson Molly | CFO and CBO | Sell | 3,678 | $4.55 | $16.7K | 0 |
| Jul 17, 2024 | Curran Terrie | President and Chief Executive | Sell | 33,848 | $11.72 | $396.7K | 377,734 |
| Jul 17, 2024 | Henderson Molly | CFO and CBO | Sell | 4,325 | $11.72 | $50.7K | 99,447 |
| Jul 17, 2024 | Nabulsi Azmi | Chief Operating Officer | Sell | 10,901 | $11.72 | $127.8K | 240,421 |
| Mar 26, 2024 | Curran Terrie | President and Chief Executive | Sell | 16,851 | $9.11 | $153.5K | 410,784 |
| Jan 25, 2024 | TAKEDA PHARMACEUTICAL CO LTD | 10% Owner | Sell | 3,703,703 | $8.10 | $30.00M4.7% OS | 3,755,583-50% |
| Jan 22, 2024 | Henderson Molly | CFO and CBO | Sell | 6,307 | $7.75 | $48.9K | 98,698 |
| Nov 21, 2023 | Henderson Molly | CFO and CBO | Sell | 2,127 | $7.24 | $15.4K | 103,061 |
| Nov 3, 2023 | Henderson Molly | CFO and CBO | Sell | 12,492 | $8.88 | $110.9K | 116,869 |
| Jun 5, 2023 | Henderson Molly | CFO and CBO | Sell | 1,960 | $11.41 | $22.4K | 68,506 |
| May 23, 2023 | Henderson Molly | CFO and CBO | Sell | 2,110 | $12.87 | $27.2K | 70,466 |
| Apr 7, 2023 | Henderson Molly | CFO and CBO | Sell | 3,439 | $7.27 | $25.0K | 72,576 |
| Mar 3, 2023 | Curran Terrie | President and Chief Executive | Sell | 1,436 | $8.54 | $12.3K | 175,371 |
| Mar 3, 2023 | Henderson Molly | CFO and CBO | Sell | 2,032 | $8.53 | $17.3K | 76,015 |
| Jan 20, 2023 | Curran Terrie | President and Chief Executive | Sell | 5,821 | $8.20 | $47.7K | 176,807 |
| Nov 23, 2022 | Curran Terrie | President and Chief Executive | Sell | 1,526 | $9.60 | $14.6K | 83,720 |
| Nov 23, 2022 | Henderson Molly | CFO and CBO | Sell | 2,159 | $9.60 | $20.7K | 43,341 |
| Mar 16, 2022 | TAKEDA PHARMACEUTICAL CO LTD | 10% Owner | Sell | 18 | $19.00 | $342.00 | 7,459,286 |
| Nov 8, 2021 | TAKEDA PHARMACEUTICAL CO LTD | 10% Owner | Sell | 1,000,001 | $20.85 | $20.85M1.3% OS | 1,100,000-48% |
| Oct 8, 2021 | Socks David A | Director | Sell | 18,000 | $32.58 | $586.4K | 1,213,875 |
| Sep 23, 2021 | Socks David A | Director | Sell | 18,000 | $32.63 | $587.4K | 1,233,770 |
| Aug 18, 2021 | Socks David A | Director | Sell | 18,000 | $31.25 | $562.5K | 1,261,137 |
| Jul 9, 2021 | TAKEDA PHARMACEUTICAL CO LTD | 10% Owner | Sell | 2,609 | $35.05 | $91.4K | 871,305 |
| Jul 6, 2021 | TAKEDA PHARMACEUTICAL CO LTD | 10% Owner | Sell | 8,326 | $35.16 | $292.7K | 874,014 |
| Jun 29, 2021 | Socks David A | Director | Sell | 40,000 | $34.05 | $1.36M | 1,275,061 |
PHAT Insiders
Similar Stocks to PHAT
VRTX
Vertex Pharmaceuticals Incorporated
$445.21+0.04%
$113.41B
REGN
Regeneron Pharmaceuticals, Inc.
$614.20+0.45%
$65.47B
ALNY
Alnylam Pharmaceuticals, Inc.
$283.35-2.09%
$40.46B
RVMD
Revolution Medicines, Inc.
$153.65+2.96%
$31.73B
UTHR
United Therapeutics Corporation
$542.43-0.54%
$23.12B
INSM
Insmed Incorporated
$98.28+1.64%
$20.41B
INCY
Incyte Corporation
$108.85+0.95%
$20.11B
MRNA
Moderna, Inc.
$50.18+1.06%
$18.89B